Personalized and Precision Cancer Care refers to tailoring treatment strategies based on an individual’s genomic profile, tumor biology, lifestyle, and environment — with the aim of improving outcomes, reducing side effects, and avoiding one-size-fits-all therapies.
What’s the Difference?
| Term | Focus | Description |
|---|---|---|
| Personalized Cancer Care | Broader approach (includes genetic, clinical, lifestyle factors) | Treats the individual patient |
| Precision Cancer Care | Data-driven (molecular, omics, AI) | Treats the tumor’s specific characteristics |
Both are often used interchangeably but precision medicine is a subset of personalized care.
Key Components of Precision Cancer Care
1. Molecular Profiling / Genomic Testing
- Identifies actionable mutations, gene fusions, copy number variations.
- Enables targeted therapies and predicts immunotherapy response.
Example Tests:
| Test Type | Purpose | Example Findings |
|---|---|---|
| NGS Panels (e.g., FoundationOne, OncoPanel) | Mutation profiling | EGFR, KRAS, BRAF, ALK |
| Whole Exome/Genome | Rare cancer exploration | Novel or rare variants |
| RNA-seq | Expression/fusion detection | NTRK, ALK fusions |
| MSI & TMB | Immunotherapy biomarkers | MSI-H, TMB-High |
2. Biomarker-Driven Therapy
| Biomarker | Cancer Type | Matched Therapy |
|---|---|---|
| HER2 overexpression | Breast, gastric | Trastuzumab |
| EGFR mutation | NSCLC | Osimertinib |
| PD-L1 expression | Melanoma, lung | Pembrolizumab, Nivolumab |
| BRCA1/2 mutation | Breast, ovary | PARP inhibitors (Olaparib) |
| RET/NTRK fusions | Multiple | Selpercatinib, Larotrectinib |
FDA has approved several “tissue-agnostic” therapies (e.g., pembrolizumab for MSI-H tumors, larotrectinib for NTRK fusions), regardless of cancer origin.
3. Liquid Biopsy & Minimal Residual Disease (MRD) Monitoring
- Detects ctDNA, exosomes, or tumor-derived RNA from blood.
- Monitors response or relapse non-invasively.
MRD tracking can now adjust therapy in real-time (e.g., escalation/de-escalation based on relapse risk).
4. Artificial Intelligence & Decision Support
- AI tools (e.g., IBM Watson, Tempus, PathAI) match molecular findings to clinical trials or therapies.
- Digital pathology, radiomics, and multi-omics platforms integrate data for automated insights.
Personalized Care = Beyond the Genome
- Pharmacogenomics: Adjusting doses based on metabolism (e.g., TPMT for 6-MP in leukemia).
- Psychosocial needs: Mental health, social support, preferences.
- Lifestyle & comorbidities: Diabetes, cardiovascular risk, functional status.
- Patient-reported outcomes (PROs): Integrated into treatment planning.
Clinical Implementation Pathway
- Diagnosis & staging
- Molecular profiling / NGS panel
- Tumor board review (including molecular pathologist)
- Precision treatment selection (targeted, immunotherapy, trials)
- Monitoring (imaging + biomarkers)
- Adapt treatment based on response / resistance
Example: Precision Oncology Programs
| Institution | Program Name | Highlights |
|---|---|---|
| Memorial Sloan Kettering | MSK-IMPACT | Matched therapy, >10,000 patients |
| MD Anderson | APOLLO & ICON Programs | Multi-omics + AI prediction |
| NCI-MATCH Trial | Nationwide tumor-genotype trial | Basket trials by mutation |
Sources:
